In the realm of atopic dermatitis treatments, the novel medication Adtralza (active ingredient: Tralokinumab) is swiftly progressing towards eligibility for insurance coverage. The 12th Drug Benefit Evaluation Committee, convened by the Health Insurance Review and Assessment Service (HIRA) on November 9th, approved coverage for Adtralza by Leo Pharma. This approval extends to its use in adults and adolescents grappling with atopic dermatitis. Similarly, GSK's 'Trelegy Ellipta Inhaler (active ingredients: Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate),' designed for maintenance therapy in adults with asthma, also received the committee's nod for coverage.

Adtralza's journey involved four Phase 3 clinical trials, incorporating 2,265 adult and adolescent patients globally, affirming its clinical efficacy and safety. Considered a medication closely linked to Dupixent, Adtralza aligns with Korean reimbursement criteria based on clinical trial evidence targeting patients using Post-cyclosporine (CyA). The approval also takes into account its side effect profile and its direct substitution relationship with Dupixent.

Trelegy 200 Ellipta, a product doubling the dosage of the existing COPD treatment, Trelegy Ellipta, has garnered approval solely for maintenance therapy in adults with asthma where LABA and ICS combination therapy is inadequately controlled. This distinct indication sets it apart from the original Trelegy Ellipta, which addresses both moderate to severe COPD and inadequately controlled asthma.

Both Adtralza and Trelegy 200 Ellipta, recognized for reimbursement appropriateness by the Drug Benefit Evaluation Committee, are progressing through negotiations with the National Health Insurance Corporation (NHIS).

In contrast, Antengene Pharmaceutical's Xpovio for multiple myeloma and Meditip's Yondelis Injection 1.0 milligrams for connective tissue tumor growth have been deemed non-reimbursable.